Published online Sep 15, 2023. doi: 10.4251/wjgo.v15.i9.1626
Peer-review started: April 26, 2023
First decision: June 7, 2023
Revised: June 17, 2023
Accepted: July 29, 2023
Article in press: July 29, 2023
Published online: September 15, 2023
The hemoglobin, albumin, lymphocyte, and platelet (HALP) score, derived from a composite evaluation of markers reflecting the tumor-inflammation relationship and nutritional status, has been substantiated as a noteworthy prognostic determinant for diverse malignancies.
To investigate how the HALP score relates to prognosis in patients with metastatic gastric cancer.
The cutoff values for the HALP score, neutrophil/lymphocyte ratio, and pla
The study cohort comprised 147 patients and 110 of them (74.8%) were male. The patients' median age was 63 (22-89) years. The median overall survival was significantly superior in the patients with high HALP scores than in those with low HALP scores (10.4 mo vs 7.5 mo, respectively; P < 0.001)
The HALP score was found to be a prognostic factor in patients with metastatic gastric cancer.
Core Tip: Median overall survival (OS) was 10.4 mo in the high hemoglobin, albumin, lymphocyte, and platelet (HALP) group and 7.5 mo in the low HALP group. There was a statistically significant difference between the groups in terms of age (P < 0.001), second-line chemotherapy (P < 0.001), sex (P = 0.035), and HALP score (P = 0.004). The HALP score has been demonstrated to be useful as a prognostic factor in a variety of cancer types, including genitourinary and gastrointestinal malignancies. Our study is the first to investigate the HALP score in patients with metastatic gastric cancer. We found that patients with high HALP scores had longer OS. Given its simplicity and low cost, we think the HALP score can be utilized to manage patients with gastric cancer.